206. 脆弱Ｘ症候群 Fragile X syndrome Clinical trials / Disease details
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05418049 (ClinicalTrials.gov) | September 8, 2022 | 31/5/2022 | Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge | Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Baclofen, Roflumilast, Memantine, and Placebo in Fragile X Syndrome | Fragile X Syndrome | Drug: Baclofen;Drug: Memantine;Drug: Roflumilast;Drug: Placebo | Children's Hospital Medical Center, Cincinnati | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 18 Years | 45 Years | All | 45 | Phase 2 | United States |
| 2 | NCT02998151 (ClinicalTrials.gov) | January 2016 | 1/12/2016 | Neurophysiological and Acute Pharmacological Studies in FXS Patients | Neurophysiological and Acute Pharmacological Studies in FXS Patients | Fragile X Syndrome | Drug: Acamprosate;Drug: Lovastatin;Drug: Minocycline;Drug: Placebo;Drug: Baclofen | Children's Hospital Medical Center, Cincinnati | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | 15 Years | 55 Years | All | 29 | Early Phase 1 | United States |